Johnson Matthey Public Limited Company

Bial-portela Ca & S.a.

Chirotech Technology Limited

Novartis Ag

Janssen Pharmaceutica Nv

Lonza Inc.

Johnson Matthey Inc.

Universita′ Degli Studi Di Udine

Novartis Pharmaceuticals Corporation

Chemo Iberica, S.a.

Krka, D.d., Novo Mesto

Antonio Zanotti-Gerosa

Jonathan Medlock

Gabriela Alexandra Grasa

Alan Dyke

Andreas Seger

David Alexander Learmonth

David Hook

Hans Guenter Nedden

Daniel Kaufmann

Erhard Bappert

Matthias Napp

Philippe Polleux

Mark Joseph Burk

Walter Leitner

Jonathan Alan Medlock

Frederick Ernest Hancock

Bernard Riss

Giancarlo Francio

Beatriz Dominguez

Brian Adger

Stephen James Roseblade

Damian Mark Grainger

William Patrick Hems

Markus Bicker

Anica Pecavar

Thomas Pullmann

Jacques Jean Marie Le Paih

Vilvanathan Sivakumar

Frank Bienewald

Bruce E Maryanoff

William Alvin Kinney

Christopher A Teleha

Alexander Beliaev

Shyamali Ghosh

Marcello Rasparini

Walter Baratta

Maurizio Taddei

Bernhard Riss

Martin Edward Fox

Luca Carcone

Steven Giboulot

Salvatore Baldino

Miguel Angel Caraucán Dávila

Elena Cini

Dario Veghini

Christophe Guillaume Malan

Julian Henschke

Luca Banfi

Romina Vitale

Gabriela Grasa

Milos Ruzic

Golo Heckmann

Thomas Ward

Christophe Malan

Julien Pierron

Laleh Jafarpour

Thomas Pullman

Daniela Herzberg

Adele Russo

Renata Riva

Tadej Stropnik

Miguel Angel CARAUCÁN DÁVILA

Darja Prudic

The present invention relates to improved processes for the preparation of ruthenium or osmium complexes comprising acetate ligands, in particular, ruthenium complexes.

Processes for preparing and using ruthenium and osmium complexes

The present invention relates to a process for hydrogenating a substrate including a carbon-heteroatom double bond, the process including the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): R, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof.

Process for hydrogenating ketones in the presence of Ru(II) catalysts

A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(&#x2212;)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX(L)]wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): wherein Ris chosen from Calkoxy and Calkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, Rcan be the same or different, and Ris alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NRRRand formic acid, [RRRNH][OOCH] and optionally formic acid, or [M][OOCH]and formic acid, wherein R, Rand Rare Calkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.

Asymmetric catalytic reduction of oxcarbazepine

The present invention relates to a process for hydrogenating a substrate comprising a carbon-heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): R, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof. 

The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a &#x3b3;-amino-&#x3b4;-biphenyl-&#x3b1;-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.

Intermediates for producing NEP inhibitors or prodrugs thereof

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described. 

Process for producing Aliskiren

Processes for producing NEP inhibitors or prodrugs thereof

A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X, X, Y, Yor Z is a C1-C10 alkyl, cycloalkyl, alkaryl, aralkyl or alkoxy substituting group. The chiral diamine may be used to prepare catalysts suitable for use in transfer hydrogenation reactions. 

Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysis

Methods of making a chiral phosphorus compound of formula (X) are disclosed: wherein R, R, Rare chiral or achiral groups selected from the list consisting of substituted or unsubstituted straight-chain, branched-chain or cyclic aliphatic or aromatic groups and in which the pair R/Rmay be interconnected to form a ring.

Chiral phosphorus compound

The present invention is directed to a process for enantioselectively preparing substituted piperidine alkanoic acid integrin antagonist compounds.

Enantioselective process for preparing a substituted alkanoic acid

Processes

A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral catalyst and a source of hydrogen, wherein: X is CH, oxygen or sulphur; R, Rand Rare the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group; and Ris alkyl or aryl, wherein: the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; and the term halogen means fluorine, chlorine, bromine or iodine.

Catalytic hydrogenation of ene-carbamates

The invention relaters to a process for the production of an (S)- or (R)-4-halo-3-hydroxybutyrate, comprising reacting a 4-haloacetoacetate with hydrogen in the presence of a solvent, the solvent being a solvent mixture, which comprises a first solvent and a second solvent, wherein the first solvent is an aliphatic alcohol, preferably methanol, ethanol or propanol, and the second solvent is aprotic and comprises at least one oxygen atom; and

Process for the hydrogenation of ketoesters

Growing community of inventors

Cambridge, United Kingdom

Antonio Zanotti-Gerosa